Last reviewed · How we verify
NCT04801719
Endoluminal Radiofrequency Ablation for the Treatment of Malignant Biliary Stenosis
NA trial testing Habib™ EndoHPB; Boston Scientific, US; former EMcision Ltd., UK in Radiofrequency Ablation in 76 participants. Completed in 31 December 2019.
31 December 2019
Quick facts
| Lead sponsor | Brno University Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 76 |
| Start date | 4 January 2010 |
| Primary completion | 31 December 2019 |
| Estimated completion | 31 December 2019 |
| Sites | 1 location across Czechia |
Drugs / interventions tested
- Habib™ EndoHPB; Boston Scientific, US; former EMcision Ltd., UK
Conditions studied
- Radiofrequency Ablation — all drugs for Radiofrequency Ablation →
- Biliary Tract Cancer — all drugs for Biliary Tract Cancer →
- Stent Complication — all drugs for Stent Complication →
- Brachytherapy — all drugs for Brachytherapy →
Sponsor
Brno University Hospital
Who can join
18 and older, any sex, with Radiofrequency Ablation or Biliary Tract Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The rationale of the study is to explore the safety and efficacy of endoluminal radiofrequency ablation prior metal stent insertion in patiens with malignant biliary stenosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04801719
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Radiofrequency Ablation
Currently open trials in the same condition.
- NCT07272187 — Endoscopic Ultrasound-guided Radiofrequency Ablation for Upper Gastrointestinal Tract Lesions · recruiting
- NCT07233616 — Risks and Benefits of Radiofrequency Ablation for Chronic Venous Insufficiency (CEAP C3-C6) in Patients Aged 80 and Over · recruiting
- NCT07098455 — Comparative Effectiveness of Genicular Nerve Radiofrequency Thermocoagulation and Intra-Articular Pulsed Radiofrequency · NA · active not recruiting
- NCT07126535 — Impact of RFA on Esophageal Distensibility and Mucosal Impedance · recruiting
- NCT07140757 — Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers · recruiting
Other Brno University Hospital trials
Trials by the same sponsor.
- NCT07468006 — Comparison of Transcutaneous and Blood CO₂ Measurement in Critically Ill Children · recruiting
- NCT07280039 — Mortality and Muscle Mass Loss in Critically Ill Patients. · not yet recruiting
- NCT07279701 — The Effect of Near-infrared Spectroscopy on the Success of Peripheral Venous Access · NA · recruiting
- NCT07245654 — Monitoring the Depth of Anesthesia and Nociception During the Induction of General Anesthesia in Pediatric Patients · recruiting
- NCT07110012 — The Role of Simulation-based Training in Resident Curriculum in Anaesthesia and Intensive Care · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04801719 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Brno University Hospital
- Last refreshed: 17 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04801719.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing